Clinical Trial: Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Randomised, Open-label, Parallel-group Study to Evaluate the Efficacy and Safety of ACTIQ (Oral Transmucosal Fentanyl Citrate) Titrated According to 2 Regimens in Patients With Cancer and

Brief Summary: The primary objective of the study is to determine whether a test titration regimen of ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain for an individual patient by attaining a successful dose of ACTIQ treatment more quickly. The successful ACTIQ dose provides a satisfactory combination of efficacy and tolerability after a single administration, as assessed by the patient.

Detailed Summary:
Sponsor: Cephalon

Current Primary Outcome: to determine if ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Teva Pharmaceutical Industries

Dates:
Date Received: October 7, 2005
Date Started: June 2004
Date Completion:
Last Updated: January 28, 2013
Last Verified: October 2005